A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold (ARBITR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2013 by Pharmstandard
Sponsor:
Information provided by (Responsible Party):
Pharmstandard
ClinicalTrials.gov Identifier:
NCT01651663
First received: July 2, 2012
Last updated: July 26, 2013
Last verified: July 2013
  Purpose

The purpose of this study is to determine whether Arbidol (Umifenovir) is effective in the treatment and Prophylaxis of Influenza and Common Cold


Condition Intervention Phase
Influenza
Drug: Arbidol (Umifenovir)
Other: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Placebo-controlled Clinical Study Investigating Efficacy and Safety of Arbidol (Umifenovir) in Treatment and Prophylaxis of Influenza and Common Cold.

Resource links provided by NLM:


Further study details as provided by Pharmstandard:

Primary Outcome Measures:
  • Duration of clinical illness among patients with common cold and influenza treated with Arbidol vs placebo. [ Time Frame: Baseline up to 20 days ] [ Designated as safety issue: No ]
  • Time to alleviation of influenza and common cold clinical symptoms [ Time Frame: Baseline up to 20 days ] [ Designated as safety issue: No ]
  • Number of Adverse Events that are probably or definitely related to Arbidol [ Time Frame: Baseline up to 20 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of clinical complications associated with influenza and common cold among treatment group vs placebo [ Time Frame: Baseline up to 20 days ] [ Designated as safety issue: No ]
  • The time to no detectable influenza virus by culture for the throat and nose swabs, assessed by PCR [ Time Frame: Day 3, Day 4, Day 5, Day 6, Day 7, Day 8 ] [ Designated as safety issue: No ]
  • Occurrence of influenza and common cold among participants in prophylaxis group diagnosed by physician according to history and physical examination and laboratory tests if was necessary [ Time Frame: Baseline up to 20 days ] [ Designated as safety issue: No ]
  • Frequency of emergence of antiviral resistance [ Time Frame: Baseline up to 20 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 840
Study Start Date: September 2011
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arbidol (Umifenovir) Drug: Arbidol (Umifenovir)
Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
Placebo Comparator: placebo Other: placebo
Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
Experimental: Arbidol (Umifenovir) prophylaxis Drug: Arbidol (Umifenovir)
Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
Placebo Comparator: placebo prophylaxis Other: placebo
Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.

Detailed Description:

Influenza virus infections result in major health and economic burdens worldwide. The World Health Organization estimates that the average global burden of interpandemic influenza is approximately 1 billion cases of influenza, from 3 to 5 million cases of severe illness, and from 300 000 to 500 000 deaths annually. Arbidol (Umifenovir) is currently licensed for the treatment and prevention of influenza in Russian Federation. Arbidol (Umifenovir) has a direct antiviral effect. Arbidol (Umifenovir) belongs to fusion inhibitors; it interacts with the virus hemagglutinin and thus prevents fusion of the viral envelope with cell membranes. The aim of the study is to obtain additional data on safety and therapeutic efficacy of investigational product Arbidol (Umifenovir) in patients with a diagnosis of influenza and common cold. Furthermore, study of viral resistance in patients with seasonal influenza infection treated with Arbidol (Umifenovir) will be performed.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed Patient Information and Informed Consent Form.
  • Male and female patients from 18 to 65 years.
  • Out-patients with uncomplicated* form of common cold or influenza.
  • Illness duration no more than 36 hours.
  • At least one episode of body temperature 38°C or higher during the past 36 hours.
  • Presence of at least one of the following symptoms: Headache, fatigue/malaise, pain/aches in muscles, fever/chills.
  • Patient's ability to adequately cooperate.

Exclusion Criteria:

  • A history of allergic reactions to the investigational drug Arbidol (Umifenovir) or hypersensitivity to the drug.
  • Illness duration over 36 hours.
  • Any complications of influenza/common cold or signs of severe or progressive disease* at the moment of selection for participation in the study.
  • A history of influenza vaccination carried out in the last 12 months.
  • Evidence of severe hematological, immunological, pulmonary, urogenital, gastrointestinal, hepatic, renal, endocrine, metabolic, psychiatric, dermatovenereological diseases, collagenoses, nutritional disorders, which are known from patient's history, physical examination or laboratory tests, that may limit the patient from participating in the study or which may affect the results of the study.
  • Participation in other clinical studies in the past 4 months.
  • Common cold or other infection during last 4 weeks before enrollment.
  • Administration of Arbidol (Umifenovir) during last 4 weeks before the onset of disease.
  • Administration of immunomodulators, interferon inducers, homeopathic, hormonal, antiviral and antibacterial drugs during last 4 weeks before the selection for participation in the study.
  • Alcohol or substance abuse.
  • Hospitalization at the moment of selection for participation in the study.
  • Pregnant or lactating women.
  • Any other associated disease or condition which, in the opinion of the investigator, might restrict or impede the patient's participation in the study or affect the study results.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01651663

Contacts
Contact: Alexander Denisenko, MD +7 495 970 00 30 aadenisenko@pharmstd.ru
Contact: Dmitriy Davydov, MD +7 495 970 00 30 dgdavydov@pharmstd.ru

Locations
Russian Federation
Research Institute of Influenza Not yet recruiting
Sankt-Petersburg, Russian Federation, 197376
Recruiting
Saratov, Russian Federation
Sponsors and Collaborators
Pharmstandard
Investigators
Principal Investigator: Oleg Kiselev, Dr.Biol.Sci. Research Instituete of Influenza
  More Information

No publications provided

Responsible Party: Pharmstandard
ClinicalTrials.gov Identifier: NCT01651663     History of Changes
Other Study ID Numbers: ARB-M1/P01-11
Study First Received: July 2, 2012
Last Updated: July 26, 2013
Health Authority: Russia: Ministry of Health of the Russian Federation

Keywords provided by Pharmstandard:
Influenza

Additional relevant MeSH terms:
Common Cold
Influenza, Human
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Orthomyxoviridae Infections

ClinicalTrials.gov processed this record on August 26, 2014